DOCSLIB.ORG

Bindex 877..922

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

j877 Index a acetone Abrus precatorius L. (jequirity bean) 804 – BAT value 520, 853 absinth 516 – blood concentration 520 absorption spectrophotometry (AS) 652–656, – clinical interpretation 522 668–671 – headspace-GC 171, 173, 519 ACE (angiotensin converting enzyme) – medical assessment 520 inhibitors – toxicity 522 – GC-MS 161 acetonitrile acebutolol – headspace-GC 171, 173 – HPLC 457 – hepatotoxicity 749 acenocoumarol 303 – protein precipitation 119 – HPLC 305 acetorphine 867 acephate acetylcholinesterase (AChE) – ADI value 596 – BAT value 853 – MAK value 596 – determination 760 – TLC 594 – enzyme stability 763 aceprometazine – half-life of inhibited AChE 762 – TBPE test 179 – metabolite binding 702 acetaldehyde (ethanal) acetylcholinesterase (AChE) inhibitor – headspace-GC 171, 173 – BAT value 853 acetamidoflunitrazepam acetyldigoxin 336 – HPLC 355 – elimination half-life 841 acetaminophen, see also paracetamol – plasma/serum concentration 841 – antidote 857 acetylmethadol 867 – clinical interpretation 205 6-acetylmorphine – elimination half-life 204, 841 – elimination half-life 247 – extraction 190 – GC–MS 247 – GC 198 – pharmacokinetics 247 – GC–MS 109, 112, 116 N-acetylprocainamide – HPLC 109, 112, 116, 193 – clinical interpretation 281 – immunoassay 203 – elimination half-life 281 – intoxication 144 – immunoassay 781 – medical assessment 204 – medical assessment 281 – metabolism 206 – metabolism 281 – plasma/serum concentration 841 – serum concentration 281 – serum concentration 204 acetylsalicylic acid 209 – toxic hemorrhagic disorder 751 – clinical interpretation 213 acetazolamide – elimination half-life 841 – acid-base balance 752 – extraction 190 Clinical Toxicological Analysis: Procedures, Results, Interpretation. Edited by Wolf-Rüdiger Külpmann Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-31890-2 878j Index – GC 198 – toxic 830 – HPLC 193 – toxin detection 830 – intoxication 144 alimemazine – medical assessment 212 – TBPE test 179 – metabolism 209 alkaloid 804 – plasma/serum concentration 841 – clavinet 806 – serum concentration 212 – plant 158 acids 804 – pyrrolizidine 748 aconitine allobarbital 873 – TBPE test 180 – immunoassay 346 Aconitum napellus L. (monkshood) 785–786 allopurinol acrolein – elimination half-life 841 – headspace-GC 171, 173 – plasma/serum concentration 841 acrylonitrile allylprodine 867 – hepatotoxicity 749 alphacetylmethadol 867 Adamsite 734 alphameprodine 867 ADI (acceptable daily intake) value 561 alphamethadol 867 Aesculus hippocastanum L. (horse alphaprodine 867 chestnut) 804 alprazolam 873 aflatoxin 748 – elimination half-life 841 ajmaline 177 – GC–MS 408 – elimination half-life 841 – metabolism 359 – GC 274 – plasma/serum concentration 841 – HPLC 273 alprenolol – plasma/serum concentration 841 – HPLC 457 – TBPE test 179 – TBPE test 180 alcohols aluminium – anemia 751 – BAT value 853 – clinical interpretation 522 Amanita pantherina 813 – headspace-GC 517 Amanita phalloides 751, 811, 819 – highly volatile 511–523 – antidote 857 – medical assessment 520 a-amanitin aldicarb 564 – ELISA 159 – ADI value 574 amanitin 812, 817 – blood/serum concentration 574 – analytical strategy 821 – clinical interpretation 574 – therapy 821 – LD50 value 573 amatoxin 811, 816 – MAK value 574 – antidote 857 – medical assessment 573 – clinical interpretation 820 – toxicity 574 – HPLC 819 aldrin 578 – LC–MS 819 – ADI value 580 – immunoassay 817 – blood/plasma/serum concentration 581 – intoxication 820 – clinical interpretation 581 – medical assessment 819 – MAK value 580 – nephrotoxicity 749 – medical assessment 580 – screening procedure 816 – poisoning 581 – syndrome 811 – TLC 579 – toxic hemorrhagic disorder 751 – toxicity 580 Ambrosia artemisifolia 788 – toxicokinetics 580 ambroxol alfentanil 873 – HPLC 136 – elimination half-life 841 amezine – plasma/serum concentration 841 – TBPE test 180 algae amfepramone 873 Index j879 amfetamine 873 amlodipine amfetaminil 871 – elimination half-life 841 amikacin – plasma/serum concentration 841 – elimination half-life 841 amobarbital 873 – immunoassay 781 – elimination half-life 841 – plasma/serum concentration 841 – immunoassay 346 amineptin 871 – plasma/serum concentration 841 e-aminocaproic acid amphetamine 463–470, 873 – creatine kinase activity 750 – clinical interpretation 469 aminocarb – creatine kinase activity 750 – TLC 572 – drug-induced seizure 750 7-aminoflunitrazepam – elimination half-life 841 – HPLC 355 – GC-MS 109, 112, 116, 158, 467 aminoglycosides – HPLC 109, 112, 116, 467–469 – acid-base balance 752 – immunoassay 466 aminophenazone – medical assessment 469 – extraction 190 – metabolism 464 – GC 198 – minimal concentration to be detected 75 – HPLC 193 – plasma/serum concentration 841 aminorex 871 – TBPE test 179 5-aminosalicylic acid amphotericin B – elimination half-life 841 – acid-base balance 752 – plasma/serum concentration 841 – elimination half-life 841 aminothiol 699 – plasma/serum concentration 841 – GC–MS 700 ampicillin amiodarone – elimination half-life 841 – clinical interpretation 275 – plasma/serum concentration 841 – elimination half-life 275, 841 amrinone – GC 274 – elimination half-life 841 – GC–MS 109, 112, 116 – plasma/serum concentration 841 – HPLC 109, 112, 116, 273 amygdalin 806 – medical assessment 275 iso-amyl acetate (iso-pentyl acetate) – metabolism 276 – headspace-GC 172, 174 – plasma/serum concentration 841 n-amyl acetate (pentyl acetate) – serum concentration 275 – headspace-GC 172, 174 – TBPE test 179 analgesics 215–265 amisulpride – acid-base balance 752 – GC–MS 408 – group immunoassay 216 amitriptyline 414, 432–434 analgesics, nonopioid 189–214 – clinical interpretation 432–434 – GC-MS 158 – elimination half-life 841 analysis, toxicological – GC 405 – chemicals 8 – GC–MS 109, 112, 116, 408 – devices 5 – HPLC 109, 112, 116, 136, 397, 401 – impact 1, 96 – immunoassay 781 – management 7 – medical assessment 432–434 – methods 6 – metabolism 433 – personnel 8 – overdose 434 – technical requirements 7 – plasma/serum concentration 841 analytical assessment 77 – serum concentration 414, 435 analytical result – TBPE test 179 – assessment 77–79 amitriptyline-N-oxide analytical toxicological report 81–86 – GC–MS 408 – delivery 86 – TBPE test 179 anemia 880j Index – associated drug 751 – oral 615–619 anesthetics – poisoning 753 – acid-base balance 752 antidote 857–859 – drug-induced seizure 750 – monitoring 754 – local 158 antidysrhythmic agent 271–284 angels trumpet (Brugmansia sanguinea L.) – GC–MS 158 785–786 – HPLC 273 angiotensin receptor blockers – immunoassay 272 – GC-MS 161 antihistamines (H1 antagonists) anileridine 867 – antidote 857 aniline – drug-induced seizure 750 – BAT value 853 – GC-MS 158 – headspace-GC 171, 174 anti-inflammatory drug aniline derivative – nonsteroidal 751 – anemia 751 antimalarial agent animal – anemia 751 – diagnosis of poisoning caused by antimony animal 825 – hepatotoxicity 749 – marine 826 – nephrotoxicity 749 – terrestrial 831 antineoplastic drugs – venomous and poisonous 825–834 – IA, HPLC, LC–MS 159 antazoline antiparkinsonian agents – TBPE test 179 – antidote 857 anticoagulants 301–311 – GC-MS 158 – anemia 751 antipsychotics – GC-MS 161 – drug-induced seizure 750 – HPLC 303 antipyrine, see also phenazone – mechanism of action 302 – clinical interpretation 208 – screening method 302 – elimination half-life 207, 841 – toxic hemorrhagic disorder 751 – GC 198 anticonvulsants 287–300 – GC–MS 113 – GC-MS 158 – HPLC 113, 193 – HPLC 289 – medical assessment 207 – immunoassay 288 – metabolism 208 antidepressants 393–452 – plasma/serum concentration 841 – color test 394 – serum concentration 207 – drug-induced seizure 750 antirheumatics 189–214 – GC-MS 158 antirheumatics, nonsteroidal – group assay 393 – GC-MS 161 – HPLC 396 Apocynum cannabinum (dog bane) 806 – immunoassay 393 aprobarbital – intoxication 139 – elimination half-life 841 – tricyclic – immunoassay 346 – antidote 433, 857 – plasma/serum concentration 841 – intoxication 432 Areca catechu (betel nut) 799 – minimal concentration to be detected 75 Argyreia nervosa (Hawaiian baby wood rose) – poisoning 753 806 – tetracyclic Arisaema spp. 789–790 – minimal concentration to be detected 75 aripiprazole antidiabetics 613–621 – elimination half-life 841 – drug-induced seizure 750 – GC–MS 408 – GC–MS 161 – plasma/serum concentration 841 – HPLC–MS 615 aromatics (BTEX) 523–531 – LC–MS 618–619 – GC 523 Index j881 – headspace-GC 526 barbiturates 339–350 arsenic – GC-MS 158, 161 – antidote 857 – minimal concentration to be detected 75 – liver toxin 748 – poisoning 753 – nephrotoxicity 749 BDB (benzodioxazolylbutanamine) 463–464 arsine Begonia spp. 789–790 – anemia 751 bendiocarb – hepatotoxicity 749 – ADI value 574 – nephrotoxicity 749 – LD50 value 573 assessment of analytical results 77 – MAK value 574 – analytical 77 benomyl – biological 78 – ADI value 574 – nosological 79 – MAK value 574 Artemisia absinthium L. 804 benperidol astemizole – GC 405 – TBPE test 179 – GC–MS 408 atenolol 458 – HPLC 397 – elimination half-life 841 – TBPE test 180 – GC–MS 109, 112, 116 benzaldehyde – HPLC 109, 112, 116, 457 – headspace-GC 171, 174 – metabolism 458 benzalkonium chloride – plasma half-life 458 – TBPE test 179 – plasma/serum concentration 458, 841 benzbromarone atomic absorption spectrometry (AAS) 664 – elimination half-life 842 Atropa belladonna L. (deadly nightshade) 785 – HPLC 305 – antidote 857 – plasma/serum concentration 842 atropine 791 benzene – elimination half-life 842 – BAT value 527 – plasma/serum concentration 842
Recommended publications
  • Meprobamate Art 107 AR

    Meprobamate Art 107 AR

    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)

    Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)

    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach

    Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach

    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS

    Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS

    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column

    Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column

    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
  • XXI. Gtfch-Symposium Poster

    XXI. Gtfch-Symposium Poster

    Toxichem Krimtech 2019;86(2):145 XXI. GTFCh-Symposium Poster P01 Impact of the NpSG on the number of hospitalisations due to NPS use Michaela Sommer1, Sebastian Halter1, Verena Angerer3, Volker Auwärter1, Maren Hermanns- Clausen2 1 Institut für Rechtsmedizin, Universitätsklinikum, Freiburg 2 Zentrum für Kinder- und Jugendmedizin, Vergiftungs-Informations-Zentrale, Universitätsklinikum, Freiburg 3 Institut für Rechtsmedizin, Kantonsspital St. Gallen, St. Gallen, Schweiz Aims: New psychoactive substances (NPS) have become a lasting threat to public health for many years. To prevent the emergence and spread of NPS, a new German law, the ‘NpSG’ (act on NPS), took effect in November 2016. This study presents an overview of analytically confirmed NPS intoxications during a 4-year period. To demonstrate effects of the act, the results of two years before and after the introduc- tion of the law were compared. Methods: Within the scope of a prospective observational study blood and urine samples were collected from emergency patients with suspected NPS intoxication. Compre- hensive drug analyses were performed by LC-MS/MS analysis. Results and Discussion: In the period considered, 137 patients were included. SC intake was verified in 63 cases (70%) in the 2-year period before and in 27 cases (77%) after the law change, respectively. Designer stimulants or hallucinogenic drugs were tested positive in 11 cases (12%) in the first period and in 15 cases (31%) in the second period. Since February 2017, four different SCs (cumyl-PEGACLONE, 5F-MDMB-P7AICA, EG-018, 5F-cumyl-P7AICA) not covered by the NpSG were detected in six cases. In the first period the most prevalent SC in the samples was MDMB-CHMICA (21 cases).
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Pain Management 101

    Pain Management 101

    PAIN MANAGEMENT 101 By: Vicki McCulloch RN, NP & DeAnna Looper RN, CHPN, CHPCA Expect more from us. We do. Objectives • Identify a step-wise approach to pain management. • Identify the WHO Pain Ladder. • Identify non-pharmacological pain control measures. • Identify adjuvant treatment measures. • Identify common myths and truths • Identify common side effects and treatment options. Expect more from us. We do. Pain Management Principles • Use Multi-Treatment and Multi-Discipline Approach • Combine opioids with non-opioid medications • Non-pharmaceutical approaches • Include family and caregiver in planning • Include the patient! • Coordinate with facility • Coordinate with all providers- • Primary Care Provider • Nursing Home Physician • Hospice IDG Members Expect more from us. We do. Utilize the WHO Ladder World Health Organization • (WHO) “analgesic ladder” • Follow the steps as indicated. • Determine if adjuvants are necessary. Expect more from us. We do. WHO Pain Ladder STEP 3 “Strong” opioid for severe pain +/- non-opioid +/- adjuvant STEP 2 “Mild” opioid for mild- moderate pain +/- non- opioid +/- adjuvant STEP 1 Non-opioid + / - adjuvant Expect more from us. We do. Step 1-Mild Pain NON-OPIOID MEDICATION OPTIONS • Acetaminophen (Tylenol)-(Paracetamol)-(Panadol) • Non-steroidal anti-inflammatory drugs (NSAIDs) Traditional NSAIDS Ibuprofen-(Motrin) Aspirin-(Bayer) Naproxen- (Aleve) Nabumetone-(Relafen) Cox-2 Inhibitors Celecoxib-(Celebrex) Rofecoxib-(Vioxx) Valdecoxib-(Bextra) Expect more from us. We do. Adjuvants • Antidepressants
  • Central Valley Toxicology Drug List

    Central Valley Toxicology Drug List

    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.